Vaccine hesitancy for the COVID-19 vaccine booster dose among nursing home staff fully vaccinated with the primary vaccination course in Belgium
© 2024 The Authors..
In Belgium, nursing home (NH) staff (NHS) and residents were prioritised for the initial COVID-19 vaccination and successive booster doses. The vaccination campaign for the first booster started in September 2021 in Belgian NH. Our first study about vaccine hesitancy towards the COVID-19 vaccine in Belgian NHS already showed a degree of fear for the primary vaccination course (T1). This new study aims to evaluate vaccine hesitancy to get the first booster (T2) in a population of fully vaccinated (with two doses) NHS. A random stratified sample of NHS who received the primary vaccination course (N = 954) completed an online questionnaire on COVID-19 booster hesitancy (between 25/11/2021 and 22/01/2022). NHS who hesitated or refused the booster were asked for the main reason for their hesitation/refusal. Overall, 21.0 % of our population hesitated before, were still hesitating or refused the booster, NHS that were not hesitant at T1 being 5.7 times less likely to hesitate to get the first booster dose (Adjusted OR 0.179, 95 % CI: 0.120, 0.267). Although there was a slight reduction (23.5 % to 20.1 %) in the proportion of NHS who hesitated/refused vaccination at T1 compared to T2 (p = 0.034), the fear of unknown effects was the principal reason for hesitation/refusal, already mentioned in our first study. NHS were not reassured concerning their initial fears. Given the likelihood that booster vaccinations will be necessary over the coming years, a communication strategy specific to NHS should be implemented.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Vaccine: X - 16(2024) vom: 04. Jan., Seite 100453 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Digregorio, Marina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Belgium |
|---|
| Anmerkungen: |
Date Revised 17.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jvacx.2024.100453 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368516075 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368516075 | ||
| 003 | DE-627 | ||
| 005 | 20240217232410.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240216s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jvacx.2024.100453 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM368516075 | ||
| 035 | |a (NLM)38361529 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Digregorio, Marina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccine hesitancy for the COVID-19 vaccine booster dose among nursing home staff fully vaccinated with the primary vaccination course in Belgium |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a In Belgium, nursing home (NH) staff (NHS) and residents were prioritised for the initial COVID-19 vaccination and successive booster doses. The vaccination campaign for the first booster started in September 2021 in Belgian NH. Our first study about vaccine hesitancy towards the COVID-19 vaccine in Belgian NHS already showed a degree of fear for the primary vaccination course (T1). This new study aims to evaluate vaccine hesitancy to get the first booster (T2) in a population of fully vaccinated (with two doses) NHS. A random stratified sample of NHS who received the primary vaccination course (N = 954) completed an online questionnaire on COVID-19 booster hesitancy (between 25/11/2021 and 22/01/2022). NHS who hesitated or refused the booster were asked for the main reason for their hesitation/refusal. Overall, 21.0 % of our population hesitated before, were still hesitating or refused the booster, NHS that were not hesitant at T1 being 5.7 times less likely to hesitate to get the first booster dose (Adjusted OR 0.179, 95 % CI: 0.120, 0.267). Although there was a slight reduction (23.5 % to 20.1 %) in the proportion of NHS who hesitated/refused vaccination at T1 compared to T2 (p = 0.034), the fear of unknown effects was the principal reason for hesitation/refusal, already mentioned in our first study. NHS were not reassured concerning their initial fears. Given the likelihood that booster vaccinations will be necessary over the coming years, a communication strategy specific to NHS should be implemented | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Belgium | |
| 650 | 4 | |a Booster dose | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 vaccination | |
| 650 | 4 | |a COVID-19 vaccine booster dose | |
| 650 | 4 | |a Nursing home | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Staff | |
| 650 | 4 | |a Vaccine hesitancy | |
| 700 | 1 | |a Van Ngoc, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Delogne, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Meyers, Eline |e verfasserin |4 aut | |
| 700 | 1 | |a Deschepper, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Dardenne, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Duysburgh, Els |e verfasserin |4 aut | |
| 700 | 1 | |a De Rop, Liselore |e verfasserin |4 aut | |
| 700 | 1 | |a De Burghgraeve, Tine |e verfasserin |4 aut | |
| 700 | 1 | |a Coen, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a De Clercq, Nele |e verfasserin |4 aut | |
| 700 | 1 | |a De Sutter, An |e verfasserin |4 aut | |
| 700 | 1 | |a Verbakel, Jan Y |e verfasserin |4 aut | |
| 700 | 1 | |a Cools, Piet |e verfasserin |4 aut | |
| 700 | 1 | |a Heytens, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Buret, Laëtitia |e verfasserin |4 aut | |
| 700 | 1 | |a Scholtes, Beatrice |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine: X |d 2019 |g 16(2024) vom: 04. Jan., Seite 100453 |w (DE-627)NLM299955931 |x 2590-1362 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g day:04 |g month:01 |g pages:100453 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jvacx.2024.100453 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |b 04 |c 01 |h 100453 | ||